NVDA+2.54%AAPL+1.32%GOOGL−1.62%MSFT+0.20%AMZN−0.10%TSM+1.60%SPCX+7.79%META+0.47%
StockVS

NASDAQ · Biotechnology · USD

Longeveron Inc. (LGVN) Stock Analysis

Longeveron Inc. (LGVN) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

Last Updated: October 21, 2026

LGVN

$1.43

−$0.07 (−4.67%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare LGVN with… →

LGVN Key Statistics

As of Oct 21, 2026
Trading
Open
$1.49
Previous Close
$1.50
Day's Range
1.42–1.53
52-Week Range
1.31–12.30
Volume
82.15K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
−0.20
Valuation
Market Cap
$4.56M
P/E Ratio
unprofitable
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
3.84
EPS (ttm)Profit attributable to each share over the last twelve months.
−9.90
Financials (FY)
Revenue (FY)
$1.20M−49.87%
Net Income (FY)
−$22.70M
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
3.04M
1-Year Return
−82.96%
Dividend and dates
Earnings Date
November 4, 2026estimated
Avg Volume
99.94K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

As of October 21, 2026, LGVN closed at $1.43, −82.96% over 1 year.

Longeveron Inc. (LGVN) has a market capitalization of $4.56M.

In fiscal 2025, LGVN reported revenue of $1.20M.

LGVN Stock Return by Calendar Year

Longeveron Inc. (LGVN) return since Feb 2021: what $10,000 became

1 year
$10,000 $1,704
−82.96%
5 years
$10,000 $40
−99.60%
Since Feb 2021
$10,000 $19
−99.81%

If you had invested $10,000 in Longeveron Inc. (LGVN) at the close on February 12, 2021, the earliest close on record here, it would have been worth $19 at the close on October 21, 2026: −99.81% in total, −66.68% a year, over a partial period shorter than 10 years. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−71.74%
2025−70.75%
2024−87.28%
2023−57.76%
2022−73.32%
2021 (partial year)+62.89%

As of October 21, 2026.

LGVN Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$1.20M−$22.70M−1,893.6%
2024$2.39M−$15.97M−667.8%
2023$709.00K−$21.41M−3,020.2%
2022$1.22M−$18.84M−1,541.3%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$1.20M$803.00K−$23.29M−$22.70M−1,893.6%
2024$2.39M$1.88M−$16.52M−$15.97M−667.8%
2023$709.00K$221.00K−$21.03M−$21.41M−3,020.2%
2022$1.22M$497.00K−$18.04M−$18.84M−1,541.3%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

LGVN Valuation vs Biotechnology Median

Median of 608 stocks
MetricLGVNBiotechnology medianvs median
P/S ratio3.8413.300.3x the median

Medians across 608 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of October 21, 2026.

Recent News

All 13 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Longeveron Inc. (LGVN) is capitalised at $4.56M on the latest close. It is classified in the Biotechnology industry, within the Healthcare sector. The company reports 38 employees.

Over the past 52 weeks the price has ranged from $1.31 to $12.30. LGVN last closed at $1.43 on October 21, 2026. That is −$0.07 (−4.67%) against the previous close. The latest close sits 9.16% above that 52-week low.

Financial Health

Fiscal 2025 revenue came to $1.20M. That is −49.87% against the prior fiscal year, when revenue was $2.39M. The same year closed with a net loss of $22.70M. Trailing earnings per share are −9.9.

Across the 4 fiscal years on file, revenue moves from $1.22M in 2022 to $1.20M in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative. Measured against sales, the shares trade at 3.84 times revenue. On price-to-sales that is 0.3 times the Biotechnology median of 13.3. The medians here are taken across 608 Biotechnology companies that report the metric.

The reported beta is −0.2. Annualized volatility over the trailing 5 years is 184.19%. Over the trailing twelve months the total return is −82.96%. Across 5 years the annualized return works out at −66.83%.

Growth & Income

The record shows no dividend for LGVN.

2026 is still running; the total return is −71.74% year to date. The strongest complete calendar year on file is 2023 at −57.76%; the weakest is 2024 at −87.28%. Of the 4 complete calendar years on file, 0 finished higher.

Peer Comparison

Longeveron Inc. (LGVN) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Longeveron Inc. LGVN $4.56M —
Vertex Pharmaceuticals Incorporated VRTX $132.95B 30.4
Moderna, Inc. MRNA $98.14B —
Regeneron Pharmaceuticals, Inc. REGN $82.95B 19.9

The Biotechnology industry average P/E ratio is 16.6x. Longeveron Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$132.95B

 MRNA

Moderna, Inc.

$98.14B

 REGN

Regeneron Pharmaceuticals, Inc.

$82.95B

 ARGX

argenx SE

$55.97B

 ONC

BeOne Medicines AG

$43.97B

 RVMD

Revolution Medicines, Inc.

$41.64B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

 JNJ

Johnson & Johnson

$621.22B

 ABBV

AbbVie Inc.

$503.27B

 UNH

UnitedHealth Group Incorporated

$374.30B

 MRK

Merck & Co., Inc.

$369.78B
View all Healthcare stocks →

About Longeveron Inc.

Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions in the United States. Its lead investigational product is the LOMECEL-B, an allogeneic mesenchymal stem cell formulation sourced from the bone marrow of young and healthy adult donors which is in phase 3 clinical trial to treat hypoplastic left heart syndrome; completed phase 2a clinical trial to treat Alzheimer's disease, as well as in phase 2b clinical trial to treat aging frailty. The company was incorporated in 2014 and is headquartered in Miami, Florida.

Visit website →